Anti-Human GD2 (Naxitamab) - Fc Muted™ - 500 µg

Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

Neuroblastoma is an extracranial childhood cancer that accounts for 12% of cancer deaths in children 1. Neuroblastomas highly express the antigen GD2, a glycolipid that assists in the attachment of tumor cells to the extracellular matrix 2. Naxitamab (hu3F8) is a humanized IgG1 anti-GD2 monoclonal antibody developed for the treatment of neuroblastoma, osteosarcoma, and other GD2-positive cancers 3. Naxitamab was engineered by grafting the complementarity determining regions of murine 3F8 (m3F8) onto human IgG1 frameworks and optimizing the sequences for stability, binding kinetics to GD2, and efficiency in antibody dependent cell-mediated cytotoxicity (ADCC) 4. Naxitamab demonstrates direct cytotoxicity against neuroblastoma cell line LAN-1 in vitro and induces complement dependent cytotoxicity as well as ADCC 3, 4. Naxitamab has low level cross-reactivity with the ganglioside GD1b and no cross-reactivity with human N-CAM 4. The chemical name for naxitamab is immunoglobulin G1, anti-(ganglioside GD2) (humanized mus musculus clone hu3f8 gamma1-chain), disulfide with humanized mus musculus clone hu3f8 light-chain, dimer 3.

≥ 5.0 mg/ml

GD2 is a cell surface glycolipid present in low concentrations on skin, neural, or peripheral nerve cell surfaces. GD2 is overexpressed on neuroblastoma cells, most melanoma, and some other tumors.